Lux Capital has announced it has closed a new $350 million fund that will invest in early-stage science and technology ventures.

Lux Capital has announced it has closed a new $350 million fund that will invest in early-stage science and technology ventures.

Lux Capital, with offices in New York and Menlo Park, Calif., invests in counter-conventional, seed and early stage science and technology ventures. It was co-founded by Peter Hebert, Robert Paull and Josh Wolfe in 2000.

The new fund — Lux Ventures IV — brings the firm’s total capital under management to $700 million.

Among Lux Capital’s current healthcare investments include Kala Pharmaceuticals, clinical stage pharmaceutical company focused on treatments for ocular diseases; 3Scan, which develops 3D brain scans and digital organ reconstruction; and Aptible, a cloud-based platform designed to automate HIPAA compliance.”


http://www.thehealthcareinvestor.com/2015/04/articles/healthcare-services-investing/lux-capital-raises-350-million-fund-to-back-startup-healthcare-and-technology-companies/?utm_source=Mondaq&utm_medium=syndication&utm_campaign=View-Original

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s